Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical Studies
ConclusionThese data suggest that 3RC is a highly effective and well-tolerated treatment for photoaging. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 30, 2023 Category: Dermatology Source Type: research
The Relevant Oral Burden of Patients with Hidradenitis Suppurativa
ConclusionAs a result of the relevant oral burden in patients with HS, dentists should be part of the multidisciplinary team and oral education should be promoted among patients with HS. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 30, 2023 Category: Dermatology Source Type: research
Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis
ConclusionThe PP NRS is a content-valid and reliable PRO measure for quantifying itch severity in adults with PN in clinical trials.Trial Registration NumberNCT03181503. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 29, 2023 Category: Dermatology Source Type: research
Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical Studies
ConclusionThese data suggest that 3RC is a highly effective and well-tolerated treatment for photoaging. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 29, 2023 Category: Dermatology Source Type: research
Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
ConclusionsAmong real-world patients with psoriasis who achieved PASI90 with biologic therapy, about one-quarter lost response at 6 months, and half lost response at 18 months. Prior use of a biologic therapy and clinically meaningful skin symptoms at index, including itch and skin pain, were associated with loss of treatment response. Therefore, dermatologists may consider focusing on patient-reported symptoms as part of any intervention designed to reduce the likelihood of loss of response to biologic therapies.Trial RegistrationClinicalTrials.gov identifier, NCT02707341. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 27, 2023 Category: Dermatology Source Type: research
Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
ConclusionsThe results suggest that patients are more likely to remain on a systemic biologic therapy if they achieve near-complete or complete skin clearance, supporting the continued need to target skin clearance as a treatment goal in psoriasis.Trial RegistrationClinicalTrials.gov identifier, NCT02707341. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 27, 2023 Category: Dermatology Source Type: research
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6 –11 Years of Age with Severe Atopic Dermatitis
ConclusionsConsistent with results seen in adults and adolescents, long-term treatment with dupilumab in children aged 6 –11 years with severe AD showed an acceptable safety profile and incremental clinical benefit. A substantial proportion of children who stopped dupilumab treatment after achieving clear/almost clear skin subsequently experienced disease recurrence, and required reinitiation of dupilumab, suggesti ng that continuous treatment may be necessary for maintenance of clinical benefit.Trial RegistrationClinicalTrials.gov Identifier NCT02612454. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 26, 2023 Category: Dermatology Source Type: research
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 26, 2023 Category: Dermatology Source Type: research
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
ConclusionThese analyses confirm a continuous response over 5 years, indicating that guselkumab shows therapeutic longevity in Asian patients requiring long-term treatment for moderate-to-severe psoriasis.Trial RegistrationClinicalTrials.gov identifiers: VOYAGE 1 [NCT02207231] and VOYAGE 2 [NCT02207244]. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 26, 2023 Category: Dermatology Source Type: research
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 26, 2023 Category: Dermatology Source Type: research
Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials
ConclusionContent validation of the PP-NRS confirmed the importance of itch as a core symptom and treatment priority in AD; however, itch is not well covered in the EASI or IGA. Including the PP-NRS in clinical trials and HTAs will better capture patient-relevant benefit and response. Although various response criteria were used, no studies compared the performance of different criteria to inform which were most appropriate to compare treatments in clinical trials and HTAs. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 25, 2023 Category: Dermatology Source Type: research
Efficacy and Tolerability of a Novel Topical Treatment Containing Pea Protein and Xyloglucan in the Management of Atopic Dermatitis in Children: A Prospective, Multicenter Clinical Study
ConclusionXG-PP provided a comparable efficacy to hydrocortisone ointment in managing AD, thus representing a safe and effective steroid-sparing alternative in pediatric patients with AD.Trial RegistrationRetrospectively registered on 24 November 2021 in the ISRCTN registry: 11118799. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 23, 2023 Category: Dermatology Source Type: research
Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
ConclusionSecukinumab is the most cost-effective treatment option for patients with moderate-to-severe psoriasis compared with other commonly used biologics from the Chinese healthcare system perspective. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 23, 2023 Category: Dermatology Source Type: research
Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a f...
Source: Dermatology and Therapy - September 23, 2023 Category: Dermatology Source Type: research
